^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PM8001

i
Other names: PM8001, PM 8001
Associations
Trials
Company:
Biotheus
Drug class:
PD-L1 inhibitor, TGFβ inhibitor
Related drugs:
Associations
Trials
over2years
Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors. (ASCO 2022)
PM8001 showed an acceptable safety profile and promising anti-tumor activity in advanced solid tumors, especially in patients previously treated with checkpoint inhibitors, which supports further studies to explore the safety and efficacy of PM8001 as a monotherapy and in combination with other anti-tumor agents. Global Phase II monotherapy and combination studies are currently ongoing.
Clinical • P1/2 data
|
TGFB1 (Transforming Growth Factor Beta 1)
|
PM8001